Skip to main content

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top
Gepubliceerd in:

01-07-2009 | Case report

Capecitabine-induced cardiotoxicity mimicking myocardial infarction

Auteurs: T. Şentürk, Ö. Kanat, T. Evrensel, A. Aydinlar

Gepubliceerd in: Netherlands Heart Journal | Uitgave 7/2009

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Extract

Fluoropyrimidine chemotherapy has been a standard therapy in a range of solid tumours for many years. The cardiovascular side effects of fluoropyrimidines have been extensively reported.1 Capecitabine, a precursor of 5-FU, is an oral fluoropyrimidine cytotoxic agent developed with the aim of providing a more effective and less toxic alternate to 5-FU. Capecitabine has significantly less serious toxic effects than 5-FU when used alone or in combination with other cytotoxic agents2 and cardiotoxicity is an uncommon adverse effect. …
Literatuur
1.
go back to reference Becker K, Erckenbrecht JF, Haussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999;57:475–84. Becker K, Erckenbrecht JF, Haussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999;57:475–84.
2.
go back to reference McKendrick J, Coutsouvelis J. Capecitabine: effective oral fluoropyrimidine chemotherapy. Exp Opin 2005;6:231–9. McKendrick J, Coutsouvelis J. Capecitabine: effective oral fluoropyrimidine chemotherapy. Exp Opin 2005;6:231–9.
3.
go back to reference Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.
4.
go back to reference Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263–302. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263–302.
5.
go back to reference Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181–91. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181–91.
6.
go back to reference Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993;11:2405–10. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993;11:2405–10.
7.
go back to reference Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704–12. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704–12.
8.
go back to reference Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63:217–36. Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63:217–36.
9.
go back to reference Schnetzler B, Popola N, Collao Lamb C, Sappino AP. Coronary spasm induced by capecitabine. Ann Oncol 2001;12:723–4. Schnetzler B, Popola N, Collao Lamb C, Sappino AP. Coronary spasm induced by capecitabine. Ann Oncol 2001;12:723–4.
10.
go back to reference Bertolini A, Fumano M, Fusco O, Muffatti A, Scarinci A, Pontiggia G, et al. Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 2001;87:200–6. Bertolini A, Fumano M, Fusco O, Muffatti A, Scarinci A, Pontiggia G, et al. Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 2001;87:200–6.
11.
go back to reference Desramé J, Bronstein JA, Thiolet C, Bredin C, Ceccaldi B, Vergeau B, et al. Coronary insufficiency after an oral intake of capecitabine. Gastroenterol Clin Biol 2001;25:829–30. Desramé J, Bronstein JA, Thiolet C, Bredin C, Ceccaldi B, Vergeau B, et al. Coronary insufficiency after an oral intake of capecitabine. Gastroenterol Clin Biol 2001;25:829–30.
12.
go back to reference Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrash H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002;13:795–801. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrash H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002;13:795–801.
13.
go back to reference Kuppens IE, Boot H, Beijnen JH, Schellens JH, Labadie J. Capecitabine induces severe angina-like chest pain. Ann Intern Med 2004;140:494–5. Kuppens IE, Boot H, Beijnen JH, Schellens JH, Labadie J. Capecitabine induces severe angina-like chest pain. Ann Intern Med 2004;140:494–5.
14.
go back to reference Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990;65:885–9. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990;65:885–9.
15.
go back to reference Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracilinduced coronary vasospasm with calcium channel blockers. Am J Med 1998;85:750–1. Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracilinduced coronary vasospasm with calcium channel blockers. Am J Med 1998;85:750–1.
Metagegevens
Titel
Capecitabine-induced cardiotoxicity mimicking myocardial infarction
Auteurs
T. Şentürk
Ö. Kanat
T. Evrensel
A. Aydinlar
Publicatiedatum
01-07-2009
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 7/2009
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086265